SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced that Neill Giese, Ph.D., Chief Scientific Officer, presented preclinical data on CAL-101, an oral p110 delta selective PI3K inhibitor, and CAL-120, an oral PI3K inhibitor with p110 beta inhibition, during a PI3K symposium at the American Association for Cancer Research 100th Annual Meeting 2009 in Denver, Colorado. In addition, Dr. Heather Webb of Calistoga Pharmaceuticals presented preclinical data on the favorable nonclinical safety and pharmacokinetics of CAL-101 during a poster session.
